Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteo, a developer of compounds for biological and medical research, and its wholly-owned subsidiary Proteo Biotech, have announced the beginning of patient recruitment for a Phase II carcinoma clinical trial.
Subscribe to our email newsletter
In this randomized, placebo-controlled Phase II trial the effect of Elafin on inflammatory parameters will be investigated in patients undergoing esophagectomy for esophagus carcinoma. The trial will be performed under the direction of professor Fred Frich of the department of general and thoracic surgery, University of Kiel.
Birge Bargmann, CEO of Proteo, said: “As the second largest university hospital in Germany, the University Hospital of Schleswig-Holstein offers an ideal infrastructure for performing a trial of this type. We are confident that the results of the trial will provide confirmation of the mode of action and so promote our multifaceted development program for Elafin.”